Efficacité des veinoglobulines dans le scléromyxœdème d’Arndt-Gottron

Heymann, 2007, Scleromyxedema, J Am Acad Dermatol, 57, 890, 10.1016/j.jaad.2007.04.033 Rongioletti, 2008, Treatment of localized lichen myxedematosus of discrete type with tacrolimus ointment, J Am Acad Dermatol, 58, 530, 10.1016/j.jaad.2006.10.021 Harris, 1979, Treatment of scleromyxedema with melphalan, Arch Dermatol, 115, 295, 10.1001/archderm.1979.04010030003002 Feldman, 1969, Scleromyxedema. A dramatic response to melphalan, Arch Dermatol, 99, 51, 10.1001/archderm.1969.01610190057010 Helm, 1987, Iatrogenic myelomonocytic leukemia following melphalan treatment of scleromyxedema, Cutis, 39, 219 Aberer, 1988, Scleromyxedema: immunosuppressive therapy with cyclophosphamide, Hautarzt, 39, 277 Hisler, 1991, Improvement of scleromyxedema associated with isotretinoin therapy, J Am Acad Dermatol, 24, 854, 10.1016/0190-9622(91)70132-L Farr, 1984, PUVA treatment of scleromyxedema, Br J Dermatol, 110, 347, 10.1111/j.1365-2133.1984.tb04642.x Helfrich, 1988, Scleromyxedema myopathy: case report and review of the literature, Arthritis Rheum, 31, 1437, 10.1002/art.1780311115 Tschen, 1999, Scleromyxedema: treatment with interferon alfa, J Am Acad Dermatol, 40, 303, 10.1016/S0190-9622(99)70471-8 Kavanagh, 1997, Electron beam therapy in Arndt-Gottron's scleromyxedema, Br J Dermatol, 137, 152, 10.1111/j.1365-2133.1997.tb03724.x Keong, 1990, Successful treatment of scleromyxedema with plasmapheresis and immunosuppression, J Am Acad Dermatol, 22, 842, 10.1016/S0190-9622(08)81176-0 Westheim, 1987, Plasmapheresis in a patient with scleromyxedema, Arch Dermatol, 123, 786, 10.1001/archderm.1987.01660300108022 Amini-Adle, 2007, Scleromyxedema: successful treatment with thalidomide in two patients, Dermatology, 214, 58, 10.1159/000096914 Caradonna, 2004, Thalidomide as a potential treatment for scleromyxedema, Arch Dermatol, 140, 277, 10.1001/archderm.140.3.277 Sansbury, 2004, Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients, J Am Acad Dermatol, 51, 126, 10.1016/j.jaad.2004.01.058 Terheyden, 2003, Treatment of scleromyxedema with hydroxychloroquine, J Dtsch Dermatol Ges, 1, 30, 10.1046/j.1610-0387.2003.t01-1-02502.x Iranzo, 2007, Scleromyxedema treated with autologous stem cell transplantation, J Eur Acad Dermatol Venereol, 21, 129, 10.1111/j.1468-3083.2006.01814.x Feasel, 2001, Complete remission of scleromyxedema following autologous stem cell transplantation, Arch Dermatol, 137, 1071 Illa, 2006, Steady remission of scleromyxedema 3years after autologous stem cell transplantation: an in vivo and in vitro study, Blood, 108, 773, 10.1182/blood-2006-01-0186 Lacy, 2005, Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantation, Arch Dermatol, 141, 1277, 10.1001/archderm.141.10.1277 Martin-Ezquerra, 2006, Papular mucinosis associated with subclinical hypothyroïdism: improvement with thyroxin therapy, J Eur Acad Dermatol Venereol, 20, 1340, 10.1111/j.1468-3083.2006.01685.x Boffa, 1995, Spontaneous improvement of scleromyxedema, Clin Exp Dermatol, 20, 157, 10.1111/j.1365-2230.1995.tb02673.x Jolles, 1998, Dermatological uses of high dose intravenous immunoglobulin, Arch Dermatol, 134, 80, 10.1001/archderm.134.1.80 Larroche, 2002, Mechanisms of intravenous immunoglobulin action in the treatment of autoimmune disorders, Biodrugs, 16, 47, 10.2165/00063030-200216010-00005 Lam, 1993, Immunologically active proteins in intravenous immunoglobulin, Lancet, 342, 678, 10.1016/0140-6736(93)91784-J Lister, 2000, Scleromyxedema: response to high dose intravenous immunoglobulin (hdIVIG), J Am Acad Dermatol, 43, 403, 10.1067/mjd.2000.104001 Righi, 2002, Intravenous immunoglobulins control scleromyxedema, Ann Rheum Dis, 61, 59, 10.1136/ard.61.1.59 Kulczycki, 2003, Scleromyxedema: treatment of cutaneous and systemic manifestations with high dose intravenous immunoglobulin, Br J Dermatol, 149, 1276, 10.1111/j.1365-2133.2003.05682.x Karim, 2004, Successful treatment of scleromyxedema with high dose intravenous immunoglobulin, Clin Exp Dermatol, 29, 317, 10.1111/j.1365-2230.2004.01518.x Shergill, 2005, Dementia associated with scleromyxedema reversed by high dose intravenous immunoglobulin, Br J Dermatol, 153, 650, 10.1111/j.1365-2133.2005.06710.x Gholam, 2007, Arndt-Gottron scleromyxedema: successful therapy with intravenous immunoglobulins, Br J Dermatol, 157, 1058, 10.1111/j.1365-2133.2007.08169.x Blum, 2008, Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG), Medicine (Baltimore), 87, 10, 10.1097/MD.0b013e3181630835 Körber, 2007, Successful therapy of scleromyxedema Arndt-Gottron with low dose intravenous immunoglobulin, J Eur Acad Dermatol Venereol, 21, 553 Efthimiou, 2008, Intravenous gammaglobulin and thalidomide may be an effective therapeutic combination in refractory scleromyxedema: case report and discussion of the literature, Semin Arthritis Rheum, 24